471 related articles for article (PubMed ID: 7692074)
1. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
2. Association of p53 mutations with metastatic prostate cancer.
Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
[TBL] [Abstract][Full Text] [Related]
3. Frequency and characterization of p53 mutations in clinically localized prostate cancer.
Hall MC; Navone NM; Troncoso P; Pollack A; Zagars GK; von Eschenbach AC; Conti CJ; Chung LW
Urology; 1995 Mar; 45(3):470-5. PubMed ID: 7879337
[TBL] [Abstract][Full Text] [Related]
4. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.
Gumerlock PH; Chi SG; Shi XB; Voeller HJ; Jacobson JW; Gelmann EP; deVere White RW
J Natl Cancer Inst; 1997 Jan; 89(1):66-71. PubMed ID: 8978408
[TBL] [Abstract][Full Text] [Related]
5. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.
Dahiya R; Deng G; Chen KM; Chui RM; Haughney PC; Narayan P
Br J Cancer; 1996 Jul; 74(2):264-8. PubMed ID: 8688333
[TBL] [Abstract][Full Text] [Related]
6. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors.
Meyers FJ; Gumerlock PH; Chi SG; Borchers H; Deitch AD; deVere White RW
Cancer; 1998 Dec; 83(12):2534-9. PubMed ID: 9874460
[TBL] [Abstract][Full Text] [Related]
7. p53 in prostate cancer: frequent expressed transition mutations.
Chi SG; deVere White RW; Meyers FJ; Siders DB; Lee F; Gumerlock PH
J Natl Cancer Inst; 1994 Jun; 86(12):926-33. PubMed ID: 7515114
[TBL] [Abstract][Full Text] [Related]
8. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
10. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer.
Dinjens WN; van der Weiden MM; Schroeder FH; Bosman FT; Trapman J
Int J Cancer; 1994 Mar; 56(5):630-3. PubMed ID: 8314337
[TBL] [Abstract][Full Text] [Related]
11. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
[TBL] [Abstract][Full Text] [Related]
12. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy.
Incognito LS; Cazares LH; Schellhammer PF; Kuban DA; Van Dyk EO; Moriarty RP; Wright GL; Somers KD
Int J Oncol; 2000 Oct; 17(4):761-9. PubMed ID: 10995889
[TBL] [Abstract][Full Text] [Related]
14. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations.
Mottaz AE; Markwalder R; Fey MF; Klima I; Merz VW; Thalmann GN; Ball RK; Studer UE
Prostate; 1997 Jun; 31(4):209-15. PubMed ID: 9180930
[TBL] [Abstract][Full Text] [Related]
15. p53 oncogene mutations in human prostate cancer specimens.
Voeller HJ; Sugars LY; Pretlow T; Gelmann EP
J Urol; 1994 Feb; 151(2):492-5. PubMed ID: 7904314
[TBL] [Abstract][Full Text] [Related]
16. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma.
Lim BH; Soong R; Grieu F; Robbins PD; House AK; Iacopetta BJ
Int J Cancer; 1996 Jun; 69(3):200-4. PubMed ID: 8682588
[TBL] [Abstract][Full Text] [Related]
17. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
[TBL] [Abstract][Full Text] [Related]
18. Identification of p53 mutations in archival prostate tumors. Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay.
Shi XB; Bodner SM; deVere White RW; Gumerlock PH
Diagn Mol Pathol; 1996 Dec; 5(4):271-8. PubMed ID: 8955619
[TBL] [Abstract][Full Text] [Related]
19. p53 gene alterations in human prostate carcinoma.
Effert PJ; McCoy RH; Walther PJ; Liu ET
J Urol; 1993 Jul; 150(1):257-61. PubMed ID: 8510267
[TBL] [Abstract][Full Text] [Related]
20. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
